Sputum cytokine repeatability in COPD
Year: 2024
Type: conference-abstract
Study design: Observational Study
Abstract: Background: Immunoassays are commonly used to assess airway inflammation in sputum samples from COPD patients. We have previously validated a Luminex assay able to quantify 20 analytes in sputum supernatant according to current regulatory standards [1]. The repeatability of these biomarkers over time in COPD patients is not known. Methods: Biomarkers were measured in paired sputum supernatant samples from COPD patients collected 6 and 12 months apart (n=48 and 18 respectively) using the validated assay. Results: 14 panel analytes were detectable. Repeated sputum biomarker measurements showed a significant positive correlation between baseline and 6 months for 13 analytes with intraclass correlation coefficient (ICC) indicating excellent repeatability (>0.75) for 7 analytes (Table 1). Similar results were observed at 12 months. Conclusion: This study demonstrates good to excellent repeatability over time in a panel of sputum supernatant biomarkers quantified using a validated Luminex assay. [1] Mulvanny, A et al, Biomedicines 2022; 10, 1949. Table 1 erj;64/suppl_68/PA2994/TB1 T1 TB1 Analyte 6 Month Repeatability (n=48) Correlations (Rho) ICC IL-1β 0.62*** 0.78 IL-1RA 0.26 0.42 IL-2 0.67*** 0.80 IL-4 0.54*** 0.63 IL-6 0.50** 0.72 IL-8 0.57*** 0.71 Eotaxin 0.50** 0.67 G-CSF 0.64*** 0.85 IFN-γ 0.37* 0.41 IP-10 0.72*** 0.83 MCP-1 0.44* 0.55 MIP-1α 0.64*** 0.79 MIP-1β 0.72*** 0.86 TNF-α 0.57*** 0.79 *p<0.01, **p<0.001, ***p<0.0001
Source: European Respiratory Journal
Authors: Alex Mulvanny, Augusta Beech, Tatiana Infante Parra, Dave Singh
Institutions: Medicines Evaluation Unit, University of Manchester
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4404099484